Trial site
Nottingham University Hospitals NHS Trust - City Hospital
Nottingham, NG5 1PB, United KingdomNot linked to an institution yet
- 7running trials
- 3closed trials
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 21 trial
- Status
- Active, not recruiting4 trials
- Completed3 trials
- Recruiting3 trials
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC5 trials
- Hoffmann-La Roche4 trials
- Takeda1 trial
Running trials
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827· Phase 3· Takeda· Source
Contact: Matthew Hall (principal investigator)
Recruiting
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
NCT04790253· European Organisation for Research and Treatment of Cancer - EORTC· Source
Contact: EORTC Reception
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798· Phase 3· Hoffmann-La Roche· Source
Recruiting
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source
Contact: EORTC HQ
Active, not recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
NCT04246086· Phase 1/2· Hoffmann-La Roche· Source
Active, not recruiting
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
NCT02799706· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source
Active, not recruiting
Phase III Radium 223 mCRPC-PEACE III
NCT02194842· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
NCT03467373· Phase 1· Hoffmann-La Roche· Source
Completed
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
NCT03274492· Phase 3· Hoffmann-La Roche· Source
Completed
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
NCT01979393· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source
Report an error